Vaxcyte, Inc. (PCVX) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Vaxcyte, Inc. (PCVX) Bundle
Looking to assess Vaxcyte, Inc.'s intrinsic value? Our (PCVX) DCF Calculator integrates real-world data with extensive customization features, enabling you to adjust forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -49.0 | -87.8 | -98.3 | -214.3 | -464.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 1.2 | 1.4 | 1.8 | 9.2 | 3.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -50.2 | -89.2 | -100.1 | -223.5 | -468.0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 59.0 | 386.2 | 246.0 | 931.4 | 1,080.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | -.2 | -.3 | -1.2 | -1.0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 3.4 | 29.8 | 6.8 | 9.8 | 14.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -1.2 | -1.2 | -6.6 | -5.8 | -67.9 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -53.5 | -87.8 | -100.1 | -239.6 | -468.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -49.8 | -61.1 | -127.0 | -233.5 | -529.0 | -14.6 | .0 | .0 | .0 | .0 |
| WACC, % | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 | 9.19 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -13.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -13 | |||||||||
| Net Debt | -368 | |||||||||
| Equity Value | 355 | |||||||||
| Diluted Shares Outstanding, MM | 97 | |||||||||
| Equity Value Per Share | 3.65 |
What You Will Get
- Editable Forecast Inputs: Effortlessly modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Vaxcyte, Inc. (PCVX) financial data pre-loaded to enhance your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically for you.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing efficiency.
Key Features
- Real-Life PCVX Data: Pre-filled with Vaxcyte’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Vaxcyte, Inc. (PCVX) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Vaxcyte, Inc.'s (PCVX) intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Vaxcyte, Inc. (PCVX)?
- Accurate Data: Up-to-date Vaxcyte financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and dependable valuation models for investment analysis in Vaxcyte, Inc. (PCVX).
- Biotech Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Vaxcyte, Inc. (PCVX).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Pharmaceutical Enthusiasts: Gain insights into how biotech companies like Vaxcyte, Inc. (PCVX) are valued in the market.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring intricate valuation calculations.
- Real-World Data: Vaxcyte, Inc.'s (PCVX) historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Visualizations and tables for clear, actionable results.